Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. May 27, 2024; 16(5): 822-831
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.822
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.822
Presepsin as a biomarker of bacterial translocation and an indicator for the prescription of probiotics in cirrhosis
Irina Efremova, Roman Maslennikov, Elena Poluektova, Maria Zharkova, Oxana Zolnikova, Gyunay Bagieva, Vladimir Ivashkin, Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia
Roman Maslennikov, Elena Poluektova, Vladimir Ivashkin, Department of Scientific, Scientific Community for the Promotion of the Clinical Study of the Human Microbiome, Moscow 119435, Russia
Oleg Medvedev, Filipp Romanikhin, Department of Pharmacology, Lomonosov Moscow State University, Moscow 119192, Russia
Anna Kudryavtseva, George Krasnov, Maria Fedorova, Department of Post-Genomic Research Laboratory, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia
Author contributions: Efremova I recruited patients, collected biomaterial and compiled a primary data table; Maslennikov R directly supervised the study, performed statistical analysis and wrote the initial version of the manuscript; Medvedev O, Poluektova E, Kudryavtseva A, and Zolnikova O supervised the research of patient biomaterials; Bagieva G, Romanikhin F, and Fedorova M studied patient biomaterial; Zharkova M supervised patient recruitment; Ivashkin V proposed the idea of the study and provided its overall supervision; Krasnov G carried out bioinformation processing of sequencing data; all authors have read, edited and approved the final manuscript.
Institutional review board statement: The study was approved by the Ethics Committee of Sechenov University and performed in accordance with the Declaration of Helsinki.
Clinical trial registration statement: The study was registered at https://clinicaltrials.gov (NCT05231772).
Informed consent statement: The study procedures were explained to the potential participants, and written informed consent was obtained before enrollment.
Conflict-of-interest statement: No conflicts of interest.
Data sharing statement: Data can be obtained from the corresponding author on reasonable request.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Roman Maslennikov, MD, PhD, Academic Editor, Associate Professor, Doctor, Professor, Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya str. 1, bld. 1, Moscow 119435, Russia. mmmm00@yandex.ru
Received: January 14, 2024
Revised: February 12, 2024
Accepted: April 12, 2024
Published online: May 27, 2024
Revised: February 12, 2024
Accepted: April 12, 2024
Published online: May 27, 2024
Core Tip
Core Tip: The gut–liver axis and bacterial translocation are important in cirrhosis; however, there is no available universal biomarker for cellular bacterial translocation, although presepsin may be a candidate. The level of presepsin directly correlated with the abundance in the gut microbiota of the main taxa that are substrates of bacterial translocation in cirrhosis. This biomarker, in the absence of obvious infection, seems important for assessing the state of the gut–liver axis in cirrhosis to decide on therapy targeted at the gut microbiota in this disease.